How Does Low-Dose Naltrexone Work for Inflammation?

← Back to Clinical Articles

Article: How Does Low-Dose Naltrexone Work for Inflammation?  |  Category: Inflammation  |  Authored by: Brian Lamkin, DO

What Naltrexone Is at Standard Dose

Naltrexone is an FDA-approved opioid antagonist prescribed at 50 mg daily for opioid and alcohol use disorders. At this dose, it competitively blocks mu-opioid receptors for 24 hours, preventing opioid and alcohol reward signaling. It has been used safely at this dose since 1984. Low-dose naltrexone (LDN) uses the same molecule at one-tenth the dose (0.5 to 4.5 mg), typically taken at bedtime. At this dose, the opioid receptor blockade is brief (4 to 6 hours) rather than sustained, and the pharmacological effects are mechanistically different from the standard dose. LDN is not approved for inflammatory or autoimmune conditions by the FDA. It is prescribed off-label based on a growing body of published evidence and clinical experience.

Mechanism 1: TLR4 Antagonism

The primary anti-inflammatory mechanism of LDN is antagonism of Toll-like receptor 4 (TLR4)^[1]. TLR4 is the innate immune receptor on macrophages, microglia, and dendritic cells that recognizes bacterial lipopolysaccharide (LPS) and activates the NF-kB inflammatory cascade. When TLR4 is activated, it produces TNF-alpha, IL-6, IL-1beta, and other pro-inflammatory cytokines. Naltrexone binds to TLR4 as a non-competitive antagonist, reducing TLR4 signaling and downstream cytokine production. This is the same pathway through which intestinal permeability drives systemic inflammation: LPS from the gut activates TLR4 on immune cells. LDN reduces the inflammatory response to that LPS signal. In the central nervous system, LDN antagonizes TLR4 on microglia, reducing neuroinflammation. This is the proposed mechanism for its benefits in fibromyalgia, chronic fatigue, and pain conditions with central sensitization.

Mechanism 2: Endorphin Rebound

The second mechanism is the endorphin rebound effect. When LDN is taken at bedtime, it briefly blocks opioid receptors for 4 to 6 hours during sleep. The body detects this blockade and responds with a compensatory upregulation of endogenous opioid production: beta-endorphin, met-enkephalin, and opioid growth factor (OGF). By morning, the naltrexone has cleared, and the elevated endorphin levels produce immunomodulatory effects throughout the following day^[2]. Endorphins are not merely analgesic. They promote regulatory T-cell differentiation (shifting immune balance toward tolerance), reduce inflammatory cytokine production, and modulate NK cell activity. The endorphin rebound is the mechanism most responsible for LDN's immunomodulatory effects in autoimmune conditions and is the reason the drug is dosed at bedtime rather than during waking hours.

Why the Dose Matters

The dose distinction is critical to understanding LDN. At 50 mg, naltrexone blocks opioid receptors continuously for 24 hours. There is no transient blockade, no compensatory endorphin upregulation, and no immunomodulatory effect. The anti-inflammatory and immunomodulatory mechanisms of LDN depend entirely on the brevity of the blockade. The brief blockade triggers the compensatory response. A sustained blockade prevents it. This is why LDN works and standard-dose naltrexone does not produce the same effects. It is also why dosing above 4.5 mg can reduce efficacy: the blockade becomes too prolonged for the compensatory mechanism to engage fully. Most patients achieve optimal results at 3.0 to 4.5 mg, though some require lower doses (1.0 to 2.0 mg), particularly those with high sensitivity or concurrent gut inflammation.

Evidence in Fibromyalgia

The strongest published evidence for LDN is in fibromyalgia^[3]. A double-blind, placebo-controlled crossover trial demonstrated that LDN at 4.5 mg reduced fibromyalgia pain by approximately 30 percent compared to placebo, with concurrent improvements in general satisfaction with life and mood. The mechanism is proposed to operate through microglial TLR4 antagonism: fibromyalgia is increasingly understood as a central sensitization condition driven by neuroinflammation, and LDN reduces microglial activation in the central nervous system. Subsequent studies have confirmed these findings and demonstrated that the fibromyalgia patients who respond best are those with higher baseline inflammatory markers, supporting the TLR4 mechanism.

Evidence in Crohn's Disease

Smith et al. published a pilot study demonstrating that LDN at 4.5 mg produced clinical remission in 67 percent and endoscopic response in 89 percent of patients with active Crohn's disease over a 12-week treatment period^[4]. While this was a small, open-label study, the endoscopic improvement (visible healing of mucosal inflammation confirmed by colonoscopy) is particularly significant because it demonstrates that LDN produces objective anti-inflammatory effects, not merely subjective symptom improvement. Subsequent studies have supported these findings, and LDN is increasingly used as an adjunctive therapy in inflammatory bowel disease alongside conventional immunosuppressive treatment.

Applications in Autoimmune Thyroid Disease

Clinical experience (with limited published trial data) supports LDN use in Hashimoto's thyroiditis. The proposed mechanism: LDN reduces the autoimmune inflammatory response through endorphin-mediated regulatory T-cell promotion and TLR4-mediated reduction in inflammatory cytokine production. Clinically, some patients demonstrate reduction in TPO antibody titers over 6 to 12 months of LDN use, alongside improvement in energy, brain fog, and other Hashimoto's symptoms. LDN does not replace thyroid hormone replacement. It is used as an immunomodulatory adjunct to reduce the autoimmune driver while thyroid optimization continues with bioidentical thyroid hormone.

LDN and Gut Motility

An additional clinical benefit of LDN is its effect on gut motility. At low doses, naltrexone stimulates the migrating motor complex (MMC), the interdigestive sweeping wave that clears the small intestine between meals. This prokinetic effect is clinically valuable in patients with SIBO, where impaired MMC function is a primary driver of bacterial reaccumulation after antimicrobial treatment. LDN at 1.5 to 4.5 mg at bedtime serves a dual role in SIBO patients: anti-inflammatory (reducing the systemic inflammation driven by SIBO and intestinal permeability) and prokinetic (preventing SIBO relapse by maintaining MMC function). This is one of the most practical clinical applications of LDN in functional medicine practice.

Dosing, Titration, and Practical Considerations

LDN is compounded by specialty pharmacies in capsule or liquid form. It is not available at the 0.5 to 4.5 mg dose from standard manufacturers. The titration protocol: start at 0.5 to 1.0 mg at bedtime. Increase by 0.5 mg every 1 to 2 weeks. Target dose: 3.0 to 4.5 mg, determined by clinical response and tolerability. Common initial side effects (vivid dreams, mild sleep disruption) typically resolve within 1 to 2 weeks. LDN should not be compounded with fillers that may cause sensitivity (some patients react to calcium carbonate or lactose fillers; microcrystalline cellulose is generally well tolerated). Timing is important: LDN must be taken at bedtime (between 9 PM and midnight) to produce the overnight endorphin rebound. Taking it during the day eliminates the rebound mechanism. LDN is contraindicated in patients currently taking opioid medications (it will precipitate withdrawal). A minimum 7 to 10 day opioid washout is required before initiating LDN.

What LDN Does Not Do

LDN is not a cure for autoimmune disease. It is an immunomodulator that reduces inflammatory signaling and promotes immune tolerance. It does not replace the need to identify and treat the root causes of chronic inflammation: gut permeability, dysbiosis, food antigens, nutrient deficiencies, cortisol dysregulation, and environmental exposures. LDN works best when used alongside a comprehensive functional medicine protocol that addresses these upstream drivers. Prescribing LDN without evaluating and treating the root causes of inflammation is the same conceptual error as prescribing a PPI without evaluating the cause of reflux: it modulates the downstream signal without addressing the source.

The Lamkin Clinic Approach

LDN is prescribed at The Lamkin Clinic as part of a comprehensive inflammation management protocol, not as a standalone intervention. The evaluation identifies the inflammatory drivers: hs-CRP for systemic inflammation, TPO antibodies for autoimmune thyroid activity, comprehensive stool analysis for gut dysbiosis, SIBO breath testing, fasting insulin for metabolic inflammation, vitamin D for immune regulation status, and Free T3 for thyroid function. LDN is initiated after (or concurrently with) root-cause treatment: gut restoration, food trigger elimination, nutrient repletion, stress management, and hormone optimization. The combination of root-cause treatment plus LDN produces more durable results than either approach alone.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Hutchinson MR, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20-29.
2. [2]Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672.
3. [3]Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis Rheum. 2013;65(2):529-538.
4. [4]Smith JP, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820-828.